Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events

摘要: Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events. Methods We randomly assigned 15,603 either clinically evident cardiovascular disease or multiple factors to receive (75 mg per day) 162 placebo and followed them median 28 months. The primary efficacy end point was composite myocardial infarction, stroke, death from causes. Results rate the 6.8 percent 7.3 (relative risk, 0.93; 95 confidence interval, 0.83 1.05; P = 0.22). respective principal secondary point, which included hospitalizations ischemic events, 16.7 17.9 0.92; 0.86 0.995; 0.04), severe bleeding 1.7 1.3 1.25; 0.97 1.61 percent; 0.09). among 6.6 5.5 1.2; 0.91 1.59; 0.20) causes also higher (3.9 vs. 2.2 percent, 0.01). In subgroup atherothrombosis, 6.9 7.9 0.88; 0.77 0.998; 0.046). Conclusions this trial, there suggestion benefit treatment symptomatic atherothrombosis harm factors. Overall, significantly more effective than alone reducing (ClinicalTrials.gov number, NCT00050817.)